Elderly asian senior woman wearing face mask getti 2025 02 25 02 07 05 utc

What is RSV?

Respiratory Syncytial Virus, more commonly known as RSV, is a common respiratory virus that can cause symptoms ranging from mild cold-like illness to severe lung infections, such as pneumonia and bronchiolitis. 

RSV in Older Adults: 
A Growing Health and Economic Burden 
in Asia-Pacific 

Respiratory Syncytial Virus, more commonly known as RSV, is a common respiratory virus that can cause symptoms ranging from mild cold-like illness to severe lung infections, such as pneumonia and bronchiolitis. While children are frequently affected, RSV also poses serious risks for adults, especially those aged 60 and older or with underlying health conditions like heart disease or chronic lung problems. For older adults, RSV can lead to high rates of hospitalization, longer recovery times, and a greater chance of intensive care or death compared to younger populations. 1, 2, 3

RSV poses a serious health threat to older adults in the Asia Pacific (APAC) region, where populations are rapidly aging and chronic lung and heart conditions are common. Immune decline with age increases vulnerability, leading to severe lower respiratory tract infections, hospitalizations, and complications, especially among those with conditions like chronic obstructive pulmonary disease (COPD), asthma, or heart failure. In high-income APAC countries, RSV is estimated to cause around 778,000 hospitalizations and 33,000 in-hospital deaths annually among adults aged 60 years or older.4

The spread of RSV doesn’t just threaten individuals - it can impact whole families, particularly in households with frequent contact between generations. When grandparents, parents, and children interact closely, the virus can move easily between age groups, putting vulnerable older adults at higher risk of serious illness and increasing stress for caregivers and family members. Addressing RSV is important not only for protecting seniors but also for safeguarding the health and well-being of entire families and communities across the region.5, 6

Beyond individual health, RSV imposes a substantial economic burden on healthcare systems in APAC. In 2023 alone, hospitalization costs reached USD 2.8 billion, with per-patient expenses ranging from USD 2,735 in New Zealand to over USD 12,000 in Canada and Singapore annually. Older adults in long-term care are especially at risk, contributing to higher resource use including prolonged hospital stays and intensive care. Given the high rates of hospitalization, ICU admissions, and exacerbation of underlying conditions, strategic prevention - such as vaccination and improved disease surveillance - is essential to support healthy aging and reduce strain on both families and national health economies across the APAC region. 7, 8, 9, 10

Map Asia

RSV as the Starting Point for AP-CHAAI: 
Addressing an Urgent Health Threat for Older Adults 

We are beginning with a dedicated focus on RSV because it is a rapidly emerging health priority for older adults across the Asia Pacific region.11 Recent breakthroughs in vaccine development now offer the first-ever protection against RSV for adults, making timely education and awareness essential. The disease’s considerable health and economic impact - high rates of hospitalization, severe outcomes, and escalating costs - underscores the urgent need for public and policymaker engagement on prevention strategies.12

With an initial focus on RSV, the website aims to provide actionable, up-to-date data, policy analysis, and recommendations as the APAC region confronts its aging demographics and prepares to deploy new preventive health tools. AP-CHAAI’s aim with this approach is to ensure that individuals, families, and health officials have the power to protect vulnerable older adults and build greater resilience in healthcare systems moving forward. 

DATA

Data Dashboard

In its initial form, the AP-CHAAI dashboard focuses on RSV, with in-depth analysis for Japan, Australia, China, and Vietnam. Each country page interprets available evidence, highlight the cost and access to vaccines, and provide actionable recommendations for policymakers. We aim to add data for additional countries in the region in the coming months.

Portrait of smart young beautiful asian business w 2025 03 26 13 31 34 utc

SOURCES

1. Oshima, Y., Yoshihara, K., & Kondo, M. (2024). Epidemiology and economic burden of respiratory syncytial virus infection among older adults in Japan: A claims database analysis. Human Vaccines & Immunotherapeutics.
2. IQVIA. (2024). Economic burden of respiratory syncytial virus infection among older adults. IQVIA Asia-Pacific.
3. Kim, Y. K., Kim, H. J., Lee, J. Y., Park, S., & Lee, J. (2024). Epidemiology and disease burden of respiratory syncytial virus infection in older adults in South Korea. Infection & Chemotherapy, 56(1), e11.
4. IQVIA. (2024). Economic burden of respiratory syncytial virus infection among older adults [White paper PDF].
5. Global Coalition on Aging. (2024). Report on the economic burden of RSV in APEC countries.
6. Global Coalition on Aging. (2024). RSV in APEC: The economic and societal costs of respiratory syncytial virus infection in older adults.
7. Lee, S. Y., Kim, D. H., & Park, H. J. (2024). Clinical and economic impact of respiratory syncytial virus infection among elderly patients in Asia. Journal of the Formosan Medical Association, 123(4), 301–309.
8. Talbot, H. K., Grijalva, C. G., & Griffin, M. R. (2024). Respiratory syncytial virus–associated hospitalizations and outcomes among adults: A population-based study. JAMA Network Open, 7(2), e246104.
9. Yahoo Finance. (2024, March 27). Report: RSV-associated hospitalisation costs exceed billions across Asia-Pacific.
10. Oshima, Y., Yoshihara, K., & Kondo, M. (2024). Epidemiology and economic burden of respiratory syncytial virus infection among older adults in Japan: A claims database analysis. Human Vaccines & Immunotherapeutics.
11. IQVIA. (2024). Economic burden of respiratory syncytial virus infection among older adults [White paper PDF].
12. IQVIA. (2024). Economic burden of respiratory syncytial virus infection among older adults [White paper PDF].